Case Study: An Integrated Solution to Accelerate a Radionuclide Drug Conjugate to IND
Radionuclide Drug Conjugates (RDCs) have shown great potential in early-stage tumor imaging and radioactive nuclide therapy. Read this WuXi TIDES case study to learn how the seamless transition from discovery to process development and manufacturing, across both small molecules and peptides, accelerated development of a challenging RDC candidate and IND submission. Milligram-scale discovery synthesis was completed in 1 month, and kilogram-scale manufacturing in just 3 months!
Video: How does it work? Peptide Oligonucleotide Conjugate
Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. Dive into the video to learn more.
Perspective: Empowering highly potent peptide drug conjugate scale-up with flow chemistry
In this article, we will look specifically at the development challenge faced when moving a peptide-drug conjugate (PDC) from pre-clinical (gram-scale) to phase I (kg-scale). New modality conjugations with HPAPIs and peptides – particularly for oncology targets – are now an increasingly large part of the discovery pipeline.
Peptide API & Drug Product Facility Virtual Tour
This video demonstrate WuXi TIDES unique peptide CRDMO platform, state-of-the-art facility R&D labs, API & drug product manufacturing plants.
WuXi TIDES Brochure: CRDMO platform for Oligonucleotide, Peptide and Complex Conjugate
WuXi TIDES Oligonucleotide, Peptide & Complex Conjugates Business Introduction
Webinar: Challenges and opportunities in Peptide Drug Conjugates (PDCs)
PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. Here we discuss how we overcome challenges and demonstrate opportunities through case studies.